Search

3rd Highlights of Past EHA (HOPE) in 2020 focused on Latin America a success!

November 13, 2020

Meeting Chairs:

Prof J Gribben (European Hematology Association)
Prof G Stemmelin (Argentinian Society of Hematology)

On November 13, EHA and the Argentinian Society of Hematology (SAH) kicked-off the second HOPE Latin America meeting in a virtual format.

Read more

Abstract submission & Awards

Abstract and Case Report submission is now closed. Abstract awardsIntroduced in 2021 and after 3 editions, we are excited to announce the 4th Emerging Investigators EHA-EBMT Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy 2024.

Read more

Call for interest — EHA Exam Question Writers Group

The call for interest closed on October 7, 2024. EHA would like to appoint four new members of the European Hematology Exam Question Writers Group.

Read more

How to apply for an EHA Research Grant

On this page, we explain all of the actions you'll need to take when submitting a grant application. You can also get a basic overview of the process in our EHA Research Grants diagram.

Read more

Challenging the safety of conformity: Better poster design to disseminate scientific knowledge fast

“Congratulations – your abstract was accepted for the upcoming EHA congress”.

Read more

Hematology Jobs

In this section of the EHA website, job opportunities within the field of hematology are posted, when available. Regulations

Service meant for hematologists and related disciplines.

Read more

Call for SWG scientific meeting proposals

The call for SWG scientific meeting proposals is closed. As part of its aim to educate and share novel research findings, EHA provides financial support for specialized working group (SWG) scientific meetings.

Read more

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more